The market for Acute Lung Injury is expected to rise at a CAGR of 3.5% during the forecast period of 2024 to 2032. Acute Lung Injury (ALI) is a severe medical condition in which lung tissues become inflamed and damaged, causing difficulty breathing and low blood oxygen levels. Infections, chemical exposure, and trauma are significant risk factors for ALI. The condition can progress to acute respiratory distress syndrome (ARDS), which has a high mortality rate of around 40% with the current standard of care. Increased alcohol and tobacco consumption among the population is causing an increase in lung injury cases, which is expected to drive the market for acute lung injury treatments. Additionally, air pollution and obesity can cause acute and chronic lung injuries. An increase in the elderly population is likely to create lucrative growth opportunities for industry vendors. Vendors are concentrating on the development, production, and distribution of novel therapies in order to increase their market share in the global acute lung injury treatment market.
R&D of Novel Therapies Enhancing Acute Lung Injury Treatment Market Growth
An increase in infectious diseases, such as influenza and pneumonia, can lead to a rise in ALI cases. Diverse studies investigate the use of biological agents, such as surfactant replacement therapy and anti-inflammatory drugs, to treat ALI. Despite advancements in surgical techniques and perioperative management, the incidence of postoperative ALI continues to be quite high. Postoperative ALI occurs in approximately 0% to 2% of patients undergoing major surgery. Depending on the type of surgery, the incidence of postoperative ALI ranges from 2-4% after thoracotomy for lung resection to 0.5% after cardiac surgery. In spite of advances in diagnosis and treatment, morbidity and mortality remain high. The development of advanced technologies, such as mechanical ventilation, oxygen therapy, and extracorporeal membrane oxygenation (ECMO), has increased the survival rate of patients with acute lung injury (ALI). Emerging treatment for ALI, ECMO involves oxygenating the patient's blood outside the body and then returning it to the patient. Thus, research and development of new technologies and an increased emphasis on improving patient outcomes are expected to contribute to the growth of the acute lung injury treatment market in the near future.
Increase in Unhealthy Habits in the Population
Tobacco use is a significant risk factor for ALI and COPD. The nicotine found in cigarettes can cause inflammation and scarring of the lungs. This can make it more difficult for the lungs to function normally, thereby increasing the risk of ALI and COPD. Thus, it is anticipated that the increase in the number of smokers will boost the market growth in the coming years. Electronic cigarettes and vaping products are gaining popularity among the general public. These products have been associated with an increase in ALI cases. According to the Centres for Disease Control and Prevention (CDC), the majority of E-cigarette or Vaping Use-associated Lung Injury (EVALI) cases are linked to tetrahydrocannabinol (THC)-containing e-cigarette or vaping products obtained from informal sources such as friends, family, or in-person or online dealers. In addition, the CDC received reports of 2,807 hospitalized cases of EVLAI in February 2020.
E-cigarette aerosols contain a variety of chemicals, including nicotine, flavorings, and solvents, which can be inhaled deeply into the lungs. These chemicals can cause irritation and inflammation, which can result in ALI symptoms including shortness of breath, chest pain, and coughing. In addition, it has been discovered that some e-cigarettes contain harmful substances, such as heavy metals and diacetyl, which can increase the risk of ALI. In the near future, the market statistics for acute lung injury treatment are likely to be influenced by the rising popularity of e-cigarettes and vaping products.
A rise in the elderly population causes a decline in lung function, making the elderly more vulnerable to ALI. There is a decline in lung elasticity, an increase in inflammation, and a weakening of the immune system in the elderly. These factors increase the susceptibility of the elderly to infections and inflammation.
COPD and heart disease are prevalent among the elderly. In this age group, the use of multiple medications also increases the risk of ALI. Therefore, the increase in the elderly population is anticipated to enhance market dynamics in the coming years.
Increase in Hospital Preference
During the forecast period, the hospital end-user segment is anticipated to dominate the acute lung injury treatment market. ALI is a serious medical condition that necessitates immediate and specialized hospital care. The proper treatment and management of ALI require a month of hospitalization for the majority of patients. For the treatment of ALI, hospitals have access to specialized equipment and technologies, such as mechanical ventilators, ECMO machines, and High-frequency Oscillating Ventilators (HFOV). In addition to pulmonologists, critical care specialists, and respiratory therapists, hospitals employ a team of trained healthcare professionals.
Cost of Treatment to Challenge the Market Growth
The primary obstacles impeding the growth of the acute lung injury market are the high cost of treatment drugs and the absence of a specific treatment for disease diagnosis. The low rate of digital radiography adoption is one of the significant factors inhibiting market expansion.
Direct Injury to Dominate the Market
The Acute Lung Injury Market is segmented by injury type into Direct Injury and Indirect Injury. The Direct Injury segment has a larger market share than the Indirect Injury segment. During the forecast period, the direct Injury segment will be the dominant market segment. Approximately 55% of Lung Injuries are caused by Direct Injury, and according to our research, this proportion will increase over the coming years.
Respiratory Tract Diseases Devices Expected to be the Fastest Growing Market
The Acute Lung Injury Market is segmented by Therapy into Therapy by Medication and Devices. The Medication consists of pharmacotherapy, fluid management, and inhaled nitric oxide. The devices are further classified as Mechanical ventilation and Adjunctive procedures. A CAGR of 5% is anticipated for Respiratory Tract Diseases devices throughout the forecast period. As a number of therapies are used as a supportive treatment for Acute Lung Injury, the medication segment dominates the devices segment. As numerous improvements are being made to medications for the treatment of lung injury, the medication segment will continue to dominate the market over the forecast period. In the segment of therapy, pharmacotherapy has a larger market share. Approximately 39% of ALI patients are treated with nitric oxide.
North America to Lead the Revenues, While Asia Emerges as Growth Leader
The most recent market forecast for acute lung injury treatment projects that North America will hold the largest share during the forecast period. In the near future, an increase in vaping adoption and the high prevalence of ALI are anticipated to boost market revenue in the region. Approximately 1 in 20 people in the United States, including several middle and high school students, use electronic cigarettes or vapes, according to the CDC. In 2021, North America dominated the market with a 35% revenue share. The North American region is anticipated to experience a CAGR of 3.5% throughout the forecast period. The increasing prevalence of the ALI is a significant factor in market dominance. The market is driven by the ongoing advances and research in the medical field for specific treatment of ALI, with the majority of key players located in North America. A high incidence of Acute Lung Injury is also observed in North America and Europe. In the U.S. approximately. In Europe and the United States, approximately 7.5% and 6.9% of all deaths are caused by respiratory diseases, respectively. The Asia-Pacific region is an emerging market for ALI due to the larger population and higher percentage of the geriatric population in China and Japan, respectively 16% and 28%. In recent years, the incidence of respiratory diseases in India has increased from 4.5% to 6.4%. In addition, increased awareness of health diagnostics is a significant factor in the expansion of market share. The market in this region is driven by the increasing prevalence of lung infections and the rising demand for medical devices and medications for the treatment of patients. The Asia-Pacific region holds approximately 25% of the market and is projected to grow at a CAGR of 5% during the forecast period.
Strong Drug Pipeline to Enhance Market Shares
The market is fragmented due to the presence of a significant number of market players and hospitals. Mayo Clinic, Johns Hopkins Hospital, Cleveland Clinic, Great Ormond Street Hospital, Apollo Hospitals, Tokyo Medical University Hospital, The Prince Charles Hospital, Helios Hospital, and Aster Hospitals are among the industry's key players.
Various molecules from various companies are currently in Phase II, Phase I, and Preclinical development. Similarly, the preclinical and discovery portfolios of universities contain seven and three molecules, respectively. Altor BioScience Corporation, Apeptico, Forschung und Entwicklung GmbH, Commence Bio, Inc., CompleGen, Inc., FirstString Research, Inc., GlaxoSmithKline Plc, Histocell S.L., Navigen Pharmaceuticals, Inc., Noxxon Pharma AG, Quark, Pharmaceuticals, Inc., S-Evans Biosciences, Inc., Silence Therapeutics Plc, Stemedica Cell Technologies, Inc., Windtree Therapeutics, Inc are some of the key market players.
Key Developments in the market include:
Historical & Forecast Period
This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Acute Lung Injury Treatment market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
| ATTRIBUTE | DETAILS |
|---|---|
| Research Period | 2022-2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Year | 2022 |
| Unit | USD Million |
| Segmentation | |
Injury Type
| |
Therapy
| |
End-user
| |
|
Region Segment (2022-2032; US$ Million)
|
Key questions answered in this report
